These technologies enable remote monitoring, more personalized diagnosis and treatments. While the FDA’s position has been encouraging, healthcare providers are conscious of pending stringent guidelines that will have undoubtable impact on this add-on feature, whereas drug and device developers are not used to the fast pace of technology innovation. It is clear that connectivity certainly casts doubts and risks in the cybersecurity and compliance world, particularly with patient data privacy.

Building on an already established Device Series, the inaugural Connected Devices: Cybersecurity & Compliance Summit 2018 will provide an unparalleled platform for industry stakeholders to share lessons learned, discuss common challenges and devise standard industry guidelines.